Algomedix is an emerging biopharmaceutical company focused on developing a first-in-class non-opioid drug for the treatment of multiple pain and inflammatory diseases. The company is positioned as a leader in the development of drugs targeting TRP receptor-channels for critical unmet medical needs. Additional therapeutic areas for drugs in our deep pipeline for TRP targets include treatment of chronic kidney disease, cardiac hypertrophy, ocular and dermatological diseases.
Algomedix's breakthrough therapeutic drug represents the Next-Generation Analgesic Drug for Chronic Pain and is based upon a novel approach to pain relief: blocking pain at its source in the peripheral nervous system by inhibiting excitation of specialized pain sensing nerve fiber endings in the peripheral nervous system. It demonstrates many advantages over existing pain therapeutics due to efficacy without adverse effects. This orally delivered drug demonstrates strong analgesic efficacy at reversing established hyperalgesia in multiple neuropathic and OA models with anticipated once daily dosing. Algomedix is advancing the program towards clinical trials in the US and Japan this year.

Biocom California is the leader and advocate for California’s life science sector. We work on behalf of more than 1,500 members to drive public policy, build an enviable network of industry leaders, create access to capital, introduce cutting-edge STEM education programs and create robust value-driven purchasing programs.
Founded in 1995 in San Diego, Biocom California provides the strongest public voice to research institutions and companies that fuel the local and state-wide economy. Our goal is simple: to help our members produce novel solutions that improve the human condition. In addition to our San Diego headquarters, Biocom California operates core offices in Los Angeles, Sacramento, and the San Francisco Bay Area, and satellite offices in Washington, D.C. and Tokyo. Our broad membership benefits apply to biotechnology, pharmaceutical, medical device, genomics and diagnostics companies of all sizes, as well as to research universities and institutes, clinical research organizations, investors and service providers.

NF corporation develops and manufactures world-class test and measurement equipment, they are ultra-low noise amplifiers and high-accuracy measurement modules for bioelectrical impedance measurement. NF propose optimal solutions for biometric analysis and device integration.

Based in San Diego, CA, PhenoVista’s core expertise is combining physiologically-relevant 2D and 3D cell models and quantitative fluorescence imaging with (pre)clinical assets to position them for further development or partnering, supporting both R&D and BD goals. We have access to a range of models across different therapeutic areas, including neuroscience, (immuno)-oncology, immunology, cell health (e.g., mitochondria, autophagy, lysosomal function), as well as novel genetic/sporadic models of rare diseases.
We have an extremely flexible business model and collaborative approach, and have built and transferred assays to clients, brought assays from outside in-house, or simply received fixed plates from clients to stain and image/analyzed images in silico. We can also provide back materials after testing for further analysis or run image analysis at our facility of images generated by other collaborators.

resistanceBio is a target and drug discovery platform company focused on identifying novel therapies that overcome treatment-resistant cancer and enable personalized precision medicine.
Platform: We’ve developed an in vitro and ex vivo cancer evolution model (the ResCu system®) that maps the cancer resistome by mimicking natural tumor response to treatment. ResCu and patient data combine to create our cancer resistome database. ResCu allows us to exploit novel cancer and immuno-oncology targets through deep learning and biological validation for better therapeutic outcomes for patients.

The SDSU Mission Valley Innovation District will be part of a vibrant, mixed-use development that includes parks and open space, housing, a hotel and conference center, a multi-use stadium, and easy access to public transportation. The Trolly station at SDSU Mission Valley is only three stops from the SDSU campus, as well as connections throughout the San Diego region.
The Innovation District will include 1.6 million square feet of research and innovation space developed primarily through public and private partnerships. The Innovation District will include multiple hubs, each focused on an important topic built around collaborations with multiple partners to design creative solutions to complex problems. In addition, the Innovation District will create a skilled workforce for changing industry needs.
The groundbreaking for the SDSU Mission Valley site occurred in early August 2020, with the target for the initial Innovation District hub to be completed in 2024-2025 and the build-out of the other Innovation District hubs to occur over about 10 years.

With over a decade of experience building and operating private online marketplaces for 24 of the world’s top 30 pharma, over 100 biotech companies and the NIH – Scientist.com is disrupting the way R&D is being done. Researchers on the Scientist.com platform have instant access to the world’s largest supplier network as well as the most innovative tools and technologies to help drive tomorrow’s great discoveries. And with industry leading compliance tools like COMPLi®, procurement teams and legal departments can focus on expediting research rather than managing red tape. So, if you’re looking for a leaner, more efficient way of conducting research, make Scientist.com your global partner for scientific sourcing.
 
製薬会社の世界Top30社のうち24社を含む100社以上の開発企業、そして国立衛生研究所 (NIH) などに各社専用のOnline Marketplaceを構築・運営し、10年以上の実績と経験を持つScientist.comは、研究開発業界に変革をもたらします。3,800社を超える世界最大のサプライヤーネットワークに即時にアクセスし、COMPLi®などの業界屈指のコンプライアンスツールで調達部と法務部は書類管理から解放されます。Scientist.comと共に、スマートで効率的なアウトソーシングを実現しましょう。

Stason Pharmaceuticals Inc. is a US-based pharmaceutical company developing partnerships and drugs. Stason has a successful history of partnering with the Japanese market to bring branded and generic products into the US market. Through our contract service division, Morgen Pharmaceutical Services, we offer CDMO contract services to drug-development companies for clinical trial materials, with options for commercial production of high potency products. In addition, we offer US based contract packaging, analytical testing, and clean room leasing to our partners. Our Irvine, California facility is registered as a PDMA Accredited Foreign Drug Manufacturer and can handle high potency compound as low as 0.5μg/m3.

Synochi LLC is a biotech company focused on botanical formulations. Our development team draws on the principles of Traditional Asian Medicine as well as practical experience to guide their work. Our current focus is on formulas that target various types of scarring. The improvement achieved by each formula is established using controlled human clinical trials.

Tioga Research is a Contract Research and Early Development Organization (CREDO) that supports the research and early development of skin‐applied products, offering, especially, formulation innovation and skin permeation screening services. Since 2002, the Tioga Research team has pioneered high throughput experimentation (HTE) technologies for screening skin deposition, delivery and permeation. These proprietary HTE technologies, alongside conventional systems, support innovations in skin-applied products, especially topical and transdermal drug products, and including skin care products and cosmetics. Tioga Research also offers GLP IVRT and IVPT services to evidence the bioequivalence of generic topical products. With headquarters and laboratory operations in San Diego, CA and a business presence in the UK to support clients in Europe, Tioga Research has become a preferred service provider for an impressive portfolio of clients across the Americas, Europe, Japan and the rest of Asia. Tioga Research has been a subsidiary of Encube Ethicals since early 2020, enabling clients to leverage the combined strengths of both organizations from early formulation innovation through to commercial manufacturing.

Founded as an experiment in 1960, UC San Diego scholars aren’t afraid to challenge convention if it means we can accelerate answers to our society’s most pressing issues. As one of the top 20 research universities in the world, we are driving change far beyond our walls to advance society and propel economic growth. UC San Diego's rich academic portfolio includes seven undergraduate colleges, six academic divisions and six graduate and professional schools.
Our culture of collaboration sparks discoveries that advance society and drive economic impact. Everything we do is dedicated to ensuring our students have the opportunity to become changemakers, equipped with the multidisciplinary tools needed to accelerate answers to our world’s most pressing issues.
Recognized as one of the top 15 research universities worldwide, we are sixth in the nation for total research output. The university has over 2500 active inventions and more than 1870 active U.S. and foreign patents. Over 1000 organizations currently license or have formerly used technology created at UC San Diego.
Our $1.54 billion research enterprise is situated in the heart of one of the most densely concentrated innovation hubs in the nation. UC San Diego is a unique place where fresh ideas are translated into solutions to benefit society—from climate science and the human microbiome to nanotechnology and social mobility.